AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34380867 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose regimen of 2 L PEG (Nulytely)
Number of subjects: 240
Study 32008429 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 162
Study 32008429 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 162
Study 34371175 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing diet
Number of subjects: 116
Study 34371175 — intervention group
Group type: COMPARATOR
Intervention: Blenderized diet
Number of subjects: 116
Study 36054520 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink-specific warning label (risk of cardiac effects)
Number of subjects: 435
Study 36054520 — intervention group
Group type: COMPARATOR
Intervention: General sugary drink warning label (risk of obesity)
Number of subjects: 435
Study 33957682 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Number of subjects: 0
Study 33957682 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 33957682 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 0
Study 33957682 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 0
Study 33957682 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 32932235 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid supplementation (678 mg FLAVs including quercetin, green tea catechins, and bilberry anthocyanins)
Number of subjects: 22
Study 32932235 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid supplementation
Number of subjects: 22
Study 32932235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 33789955 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe dysmenorrhoea group
Number of subjects: 188
Study 33789955 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pain
Number of subjects: 188
Study 34107492 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC sealants
Number of subjects: 77
Study 34107492 — intervention group
Group type: COMPARATOR
Intervention: Unsealed MIH‐affected molars
Number of subjects: 77
Study 34107492 — intervention group
Group type: EXPERIMENTAL
Intervention: MIH‐affected molars with yellow-brown opacities
Number of subjects: 77
Study 32113735 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU diary
Number of subjects: 61
Study 32113735 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge summary
Number of subjects: 61
Study 32113735 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 61
Study 32113735 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU diary and discharge summary
Number of subjects: 61
Study 35622137 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored nutritional guidance for FCs
Number of subjects: 63
Study 34497851 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training (RT group, n=27)
Number of subjects: 54
Study 34497851 — intervention group
Group type: COMPARATOR
Intervention: Conventional Overground Gait Training (PT group, n=27)
Number of subjects: 54
Study 35759537 — intervention group
Group type: COMPARATOR
Intervention: Standardized home‐based gut‐directed hypnosis exercises with compact disc (CD)
Number of subjects: 227
Study 35759537 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual hypnotherapy (iHT) by a therapist
Number of subjects: 227
Study 35759537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CD and iHT)
Number of subjects: 227
Study 33340297 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine (10 mg, 2 times a day for 24 weeks)
Number of subjects: 126
Study 33340297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same administration as fampridine)
Number of subjects: 126
Study 33340297 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine (10 mg, 2 times a day for 12 weeks after placebo)
Number of subjects: 126
Study 34565292 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EX) for 60 minutes at 75% of age-predicted maximum heart rate
Number of subjects: 22
Study 34565292 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NE)
Number of subjects: 22
Study 34888401 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (1800mg per os twice a day on day 1, followed by 1000mg b.i.d. for 13 days)
Number of subjects: 50
Study 34888401 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 50
Study 33844165 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroid ablation (TTA) with 15 mCi of radioiodine
Number of subjects: 32
Study 33844165 — intervention group
Group type: COMPARATOR
Intervention: Thyroidectomy (Tx) alone
Number of subjects: 32
Study 33017050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (<25 nmol/L)
Number of subjects: 351320
Study 33017050 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient vitamin D levels (25–50 nmol/L)
Number of subjects: 351320
Study 33017050 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically instrumented vitamin D increase
Number of subjects: 351320
Study 35492015 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat imagery
Number of subjects: 514
Study 35492015 — intervention group
Group type: COMPARATOR
Intervention: Control (no food imagery)
Number of subjects: 514
Study 35492015 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-meat imagery
Number of subjects: 514
Study 32138624 — intervention group
Group type: EXPERIMENTAL
Intervention: Human urinary kallidinogenase (HUK)
Number of subjects: 0
Study 32138624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35640630 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exposure to hypobaric hypoxia (HH) at 5000 m asl
Number of subjects: 48
Study 35640630 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated cardiopulmonary resuscitation (SCR)
Number of subjects: 48
Study 35640630 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) performance
Number of subjects: 48
Study 32803551 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with cetuximab
Number of subjects: 0
Study 32803551 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 0
Study 33971940 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxintong (NXT) capsule (3 pills, 3 times daily for 12 weeks)
Number of subjects: 260
Study 33971940 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxintong (NXT) capsule
Number of subjects: 260
Study 33971940 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 pills, 3 times daily for 12 weeks)
Number of subjects: 260
Study 33971940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 32814493 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxatives and abdominal massage (Group I)
Number of subjects: 90
Study 32814493 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxatives, acupoint pressure therapy (APT), and abdominal massage (Group II)
Number of subjects: 90
Study 32814493 — intervention group
Group type: COMPARATOR
Intervention: Laxatives only (Control Group)
Number of subjects: 90
Study 34875363 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 6
Study 34875363 — intervention group
Group type: COMPARATOR
Intervention: Sensory relearning
Number of subjects: 6
Study 33672691 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Program (TP) based on aerobic exercise, 15 weeks, 2 sessions per week
Number of subjects: 34
Study 33672691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 35731653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent prefusion F (RSVpreF) vaccine
Number of subjects: 0
Study 35731653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33268475 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) intervention in general practice
Number of subjects: 38
Study 33268475 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study 37914510 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency renal denervation (RDN)
Number of subjects: 337
Study 37914510 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 337
Study 33332699 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 75 mg
Number of subjects: 1518
Study 33332699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1518
Study 32467339 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen alone exposure
Number of subjects: 14
Study 32467339 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) and allergen coexposure
Number of subjects: 14
Study 32467339 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle-depleted diesel exhaust (PDDE) and allergen coexposure
Number of subjects: 14
Study 32467339 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 14
Study 35072855 — intervention group
Group type: EXPERIMENTAL
Intervention: SITA Faster strategy (SFR)
Number of subjects: 59
Study 35072855 — intervention group
Group type: COMPARATOR
Intervention: SITA Standard (SS)
Number of subjects: 59
Study 33730032 — intervention group
Group type: EXPERIMENTAL
Intervention: High THC (approximately 12% THC and < 0.05% CBD)
Number of subjects: 80
Study 33730032 — intervention group
Group type: EXPERIMENTAL
Intervention: High CBD (11% CBD and 0.50% THC)
Number of subjects: 80
Study 33730032 — intervention group
Group type: EXPERIMENTAL
Intervention: THC+CBD (approximately 7.9% THC and 8.1% CBD)
Number of subjects: 80
Study 33730032 — intervention group
Group type: COMPARATOR
Intervention: Placebo (< 0.03% THC and < 0.01% CBD)
Number of subjects: 80
Study 32639468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan (2.5 mg in suspension, daily for 3 days)
Number of subjects: 16
Study 37365489 — intervention group
Group type: EXPERIMENTAL
Intervention: New technique of intra-cesarean post placental introducer withdrawal IUD insertion (Copper T380)
Number of subjects: 840
Study 37365489 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual method for IUD insertion (Copper T380)
Number of subjects: 840
Study 34066577 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient fortified dairy-based drink (200 mL)
Number of subjects: 0
Study 34066577 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient fortified dairy-based drink (400 mL)
Number of subjects: 0
Study 34066577 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient fortified dairy-based drink (600 mL)
Number of subjects: 0
Study 34066577 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient fortified dairy-based drink (all dosages)
Number of subjects: 0
Study 34066577 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient fortified dairy-based drink
Number of subjects: 0
Study 32911319 — intervention group
Group type: EXPERIMENTAL
Intervention: OraquickⓇ HCV-Ab screening
Number of subjects: 78
Study 32911319 — intervention group
Group type: COMPARATOR
Intervention: Venipuncture HCV-Ab screening
Number of subjects: 78
Study 36200642 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose PTCy/ATG (40 mg/kg/d on days 3 and 4 for PTCy; 2.5 mg/kg on day 8 for ATG)
Number of subjects: 122
Study 36200642 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose ATG (10 mg/kg)
Number of subjects: 122
Study 33577862 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based intervention
Number of subjects: 3414
Study 33577862 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 3414
Study 34536050 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EXG)
Number of subjects: 39
Study 34536050 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 39
Study 33242631 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear measurements of trochlear morphology
Number of subjects: 66
Study 33242631 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular measurements (sulcus angle, medial trochlea slope, trochlea facet asymmetry)
Number of subjects: 66
Study 33242631 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements in PFI group
Number of subjects: 66
Study 33242631 — intervention group
Group type: COMPARATOR
Intervention: Measurements in non-PFI group
Number of subjects: 66
Study 36227597 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Cost health harms group
Number of subjects: 1514
Study 36227597 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Cost addiction group
Number of subjects: 1514
Study 36227597 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Cost groups (combined)
Number of subjects: 1514
Study 36227597 — intervention group
Group type: COMPARATOR
Intervention: Control group (investigator-created neutral videos about vaping)
Number of subjects: 1514
Study 33640388 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe vessel tortuosity
Number of subjects: 6951
Study 32945647 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 44
Study 32945647 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-responders)
Number of subjects: 44
Study 35482448 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracilis tendon graft with 2 tunnels (GT-2)
Number of subjects: 24
Study 35482448 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracilis tendon graft with 1 tunnel (GT-1)
Number of subjects: 24
Study 35482448 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus tendon graft with 2 tunnels (ST-2)
Number of subjects: 24
Study 35482448 — intervention group
Group type: COMPARATOR
Intervention: Semitendinosus tendon graft with 1 tunnel (ST-1)
Number of subjects: 24
Study 32296931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin (1 g/day)
Number of subjects: 98
Study 32296931 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (30 g/day)
Number of subjects: 98
Study 32296931 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of flaxseed and hesperidin (30 g flaxseed and 1 g hesperidin)
Number of subjects: 98
Study 32296931 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 98
Study 36283241 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and Vitamin E supplementation
Number of subjects: 23
Study 36283241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 33191781 — intervention group
Group type: EXPERIMENTAL
Intervention: DOAC
Number of subjects: 151
Study 33191781 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 151
Study 32794397 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Bulk Fill high viscosity bulk‐fill resin
Number of subjects: 116
Study 32794397 — intervention group
Group type: COMPARATOR
Intervention: Filtek Z350 XT nanoparticulate resin
Number of subjects: 116
Study 34110641 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for chronic rhinosinusitis
Number of subjects: 24
Study 34110641 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 33254288 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D U-net neural network
Number of subjects: 31
Study 33586013 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA isolates from newly diagnosed HIV-infected adults
Number of subjects: 537
Study 33586013 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA isolates
Number of subjects: 537
Study 33586013 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin-resistant MRSA isolates
Number of subjects: 537
Study 33586013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-resistant MRSA isolates
Number of subjects: 537
Study 33586013 — intervention group
Group type: EXPERIMENTAL
Intervention: All MRSA isolates
Number of subjects: 537
Study 33586013 — intervention group
Group type: EXPERIMENTAL
Intervention: ST8 MRSA clones from Tanzania
Number of subjects: 537
Study 33586013 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriage of ST8 MRSA
Number of subjects: 537
Study 32246504 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithm trained on H&E stained images
Number of subjects: 40
Study 32246504 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithm trained on Papanicolaou stained images
Number of subjects: 40
Study 32246504 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithm trained on Diff-Quik® stained images
Number of subjects: 40
Study 35779544 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive smoke-free legislation
Number of subjects: 106
Study 35779544 — intervention group
Group type: COMPARATOR
Intervention: Control group (72 middle-income countries without legislation)
Number of subjects: 106
Study 33587782 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo‐TENS (inert electrical stimulation applied over the hand)
Number of subjects: 90
Study 33587782 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo‐tDCS (sham transcranial direct current stimulation delivered to the supraorbital area)
Number of subjects: 90
Study 33587782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study 33306936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 60
Study 33306936 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 60
Study 35618550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered telephone program
Number of subjects: 415
Study 35618550 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based interactive tool
Number of subjects: 415
Study 35618550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered telephone program (high dose >12 encounters)
Number of subjects: 415
Study 35618550 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based interactive tool (high dose >1 web encounter)
Number of subjects: 415
Study 35618550 — intervention group
Group type: COMPARATOR
Intervention: Post-MI education-only group
Number of subjects: 415
Study 33752423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model developed using independent prognostic factors (Grade, T stage, liver surgery, chemotherapy, radiation recode, alpha‐fetoprotein level, fibrosis score, tumor size group, M stage)
Number of subjects: 1346
Study 33752423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 1346
Study 32280089 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromethylthionine 200 mg/day
Number of subjects: 220
Study 32280089 — intervention group
Group type: COMPARATOR
Intervention: Hydromethylthionine 8 mg/day (control)
Number of subjects: 220
Study 33778921 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation time and written results (Class 1)
Number of subjects: 432
Study 33778921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost (Class 2)
Number of subjects: 432
Study 33778921 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation time, waiting time, and lifestyle recommendations (Class 3)
Number of subjects: 432
Study 33778921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost
Number of subjects: 432
Study 33778921 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted uptake rates for health checks
Number of subjects: 432
Study 33246408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tests (SDMT, MMSE)
Number of subjects: 185
Study 33246408 — intervention group
Group type: COMPARATOR
Intervention: Physical performance tests (Astrand, TUG, STS, Stroop)
Number of subjects: 185
Study 33871159 — intervention group
Group type: EXPERIMENTAL
Intervention: Various trials (not specified)
Number of subjects: 2500
Study 33001556 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP‐4 inhibitor sitagliptin
Number of subjects: 0
Study 33001556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35984773 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobiliary stent placement
Number of subjects: 511
Study 35984773 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scoring scheme for predicting TB normalization
Number of subjects: 511
Study 35984773 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scoring scheme for predicting absence of TB normalization
Number of subjects: 511
Study 32658822 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 292
Study 32658822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 35385032 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy alone
Number of subjects: 60
Study 35385032 — intervention group
Group type: COMPARATOR
Intervention: Bridging therapy (intravenous alteplase at a standard dose of 0.9 mg/kg)
Number of subjects: 60
Study 35385032 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 34102077 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 0
Study 34102077 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 0
Study 34102077 — intervention group
Group type: EXPERIMENTAL
Intervention: Short and long sleep durations
Number of subjects: 0
Study 34102077 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable sleep as part of a healthy lifestyle
Number of subjects: 0
Study 32536527 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant-preserving anatomic reconstruction of the ATFL using ipsilateral free semitendinosus tendon autograft
Number of subjects: 53
Study 32536527 — intervention group
Group type: COMPARATOR
Intervention: Non-preserving anatomic reconstruction of the ATFL using ipsilateral free semitendinosus tendon autograft
Number of subjects: 53
Study 33310204 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma levels of growth differentiation factor 15 (GDF-15)
Number of subjects: 2552
Study 33310204 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma levels of interleukin 6 (IL-6)
Number of subjects: 2552
Study 34352135 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated video-training sessions
Number of subjects: 40
Study 34352135 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video-training)
Number of subjects: 40